Zydus gets nod for anti-inflammation drug in the US

Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US.

The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, congestive heart failure, cancer etc. and will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad, it said.

With this, the group now has more than 165 approvals and has so far filed over 300 applications for generic drugs since the commencement of the filing process in FY 2003-04.

Zydus Cadila over 21,000 people worldwide and aims to be a research-based pharmaceutical company by 2020.

Cadila Healthcare is headquartered at Ahmedabad in Gujarat and is the company is the fourth largest pharmaceutical company in India.

Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi.

In 1995 the Patel and Modi families split, with the Modi family’s share being moved into a new company called Cadila Pharmaceuticals Ltd. and Cadila Healthcare became the Patel family’s holding company.

In 2015, Cadila Healthcare acquired German Remedies.